The EU Falsified Medicines Directive (FMD) deadline looms ever closer, coming into effect in February 2019. Though this will ultimately improve transparency in the industry, adjusting to the new regulations is proving challenging for pharmaceutical companies and contract manufacturing organisations (CMOs).

Some companies may be underestimating the workload, and some may not have the financial means to invest in serialisation.

On 12th March, the European Medicines Verification Organisation (EMVO) announced that only 500 out of approximately 2,500 pharmaceutical companies have begun the onboarding process, which is an encouraging start, but unfortunately still well behind schedule.

Staffan Widengren, Director of Corporate Projects at Recipharm spoke to Tablets & Capsules magazine about the progress of pharmaceutical companies and CMOs when it comes to achieving compliance and what still needs to be done ahead of the deadlines.

Read the full article here:

Serialisation ready?